Cimetidine
Histamine-2 Receptor Antagonist — ALIMENTARY TRACT AND METABOLISM
Also known as: cimetidine HCl, cimetidine hydrochloride, tagamet, tametin, ulcedin, ulcedine, ulcerex, ulcerfen
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Cimetidine is an ofp drug in the Histamine-2 Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 1977. Its mechanism of action is classified as Histamine H2 Receptor Antagonists. DrugCentral lists 6 molecular targets, including HRH2, HRH2 and SLC47A1. Recorded indications include Duodenal ulcer disease, Gastric ulcer, Gastroesophageal reflux disease and Heartburn.
- Approval status: ofp (first approved 1977 by the FDA).
- Drug class: Histamine-2 Receptor Antagonist.
- Mechanism of action: Histamine H2 Receptor Antagonists.
- Molecular targets: HRH2, HRH2, SLC47A1 and Hrh2 (6 listed in DrugCentral).
- Indications: Duodenal ulcer disease, Gastric ulcer, Gastroesophageal reflux disease, Heartburn and Indigestion and others.
- ATC code: A02BA01 (H2-receptor antagonists).
- Molecular formula: C10H16N6S; molecular weight 252.34 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (11)
- Duodenal ulcer disease
- Gastric ulcer
- Gastroesophageal reflux disease
- Heartburn
- Indigestion
- Maintenance of Healing Duodenal Ulcer
- Multiple endocrine adenomas
- Systemic mast cell disease
- Upper gastrointestinal hemorrhage
- Upper GI Bleed Prevention
- Zollinger-Ellison syndrome
Off-label uses (4)
- NSAID-Induced Gastric Ulcer
- Pancreatic insufficiency
- Prevention of Stress Ulcer
- Urticaria
Contraindications (3)
- Disease of liver
- Impaired renal function disorder
- Malignant tumor of stomach
Mechanism & targets
| Mechanism of action (MoA) | Histamine H2 Receptor Antagonists |
|---|---|
| Established pharmacologic class | Histamine-2 Receptor Antagonist |
Molecular targets (6)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Histamine H2 receptor | HRH2 | unknown | Kd 6.58 |
| Histamine H2 receptor | HRH2 | antagonist | Kd 6.14 |
| Multidrug and toxin extrusion protein 1 | SLC47A1 | unknown | IC50 5.92 |
| Histamine H2 receptor | Hrh2 | antagonist | Ki 5.90 |
| 5-hydroxytryptamine receptor 2A | HTR2A | unknown | Ki 5.16 |
| Multidrug and toxin extrusion protein 2 | SLC47A2 | inhibitor | Ki 5.10 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1977-08-16 | FDA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A02BA01 | ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › H2-receptor antagonists |
A02BA51 | ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) › H2-receptor antagonists |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Chronic kidney disease | 402.7 |
| Body tinea | 187.7 |
| Urine abnormality | 170.7 |
| Inhibitory drug interaction | 154.3 |
| Infection susceptibility increased | 150.3 |
| Poor quality sleep | 135.1 |
| Urine leukocyte esterase positive | 130.0 |
| Lymphocyte count decreased | 129.0 |
| Glucose tolerance impaired | 115.4 |
| Bone density decreased | 97.0 |
| Culture urine positive | 91.8 |
| Impaired work ability | 87.6 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Cimetidine is on its molecule page.
| Molecular formula | C10H16N6S |
|---|---|
| Molecular weight | 252.34 g/mol |
| CAS number | 51481-61-9 |
| InChIKey | AQIXAKUUQRKLND-UHFFFAOYSA-N |
| PubChem CID | 2756 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Cimetidine used for?
DrugCentral lists the following indications for Cimetidine: Duodenal ulcer disease, Gastric ulcer, Gastroesophageal reflux disease, Heartburn, Indigestion, Maintenance of Healing Duodenal Ulcer, Multiple endocrine adenomas and Systemic mast cell disease and others.
How does Cimetidine work?
Cimetidine is classified as Histamine H2 Receptor Antagonists; its molecular targets in DrugCentral include HRH2, HRH2 (antagonist), SLC47A1 and Hrh2 (antagonist).
When was Cimetidine first approved?
Cimetidine was first approved by the FDA in 1977.
What drug class does Cimetidine belong to?
Cimetidine is in the Histamine-2 Receptor Antagonist class.
What is the chemical formula of Cimetidine?
Cimetidine has the molecular formula C10H16N6S and a molecular weight of 252.34 g/mol.
Browse: all drugs starting with C · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 645 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201051 — compound record and bioactivity
- PubChem CID 2756 — chemical identifiers
- DrugBank DB00501 — drug record
- FDA UNII 80061L1WGD — substance identity
- DailyMed: FDA labels for Cimetidine — current prescribing information (label search)
- UniProt P25021 (HRH2) — target protein
- UniProt Q96FL8 (SLC47A1) — target protein
- UniProt P28223 (HTR2A) — target protein
- UniProt Q86VL8 (SLC47A2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.